XML 103 R10.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2014
Revenues [Abstract] |
Revenues | Revenues Product Revenues The Company’s net product revenues consisted of the following for the years ended December 31:
|  | 2014 |  | 2013 |  | 2012
Products: |  |  |  |  |  |
Acetadote |  | $ | 11,906,232 |  |  | $ | 18,846,753 |  |  | $ | 37,522,180 |
Omeclamox-Pak |  | 4,111,916 |  |  | 1,045,815 |  |  | — |
Kristalose |  | 14,932,271 |  |  | 9,118,475 |  |  | 9,429,741 |
Vaprisol |  | 3,011,997 |  |  | — |  |  | — |
Caldolor |  | 2,721,346 |  |  | 2,089,655 |  |  | 992,110 |
Total net product revenues |  | $ | 36,683,762 |  |  | $ | 31,100,698 |  |  | $ | 47,944,031 |
As discussed in Note 3, the Company acquired rights to two new products, Omeclamox-Pak and Vaprisol, and both contributed to Cumberland's net revenue during 2014. On October 28, 2013, Cumberland entered into an agreement with Pernix to distribute and promote Omeclamox-Pak. Under the terms of the agreement, effective October 1, 2013, the Company began to record the revenue of this product and effective January 2014 Cumberland began distributing Omeclamox-Pak and promoting it to gastroenterologists across the United States. On February 28, 2014, Cumberland entered into an agreement with Astellas to acquire Vaprisol including certain product rights, intellectual property and related assets. The Company began selling Vaprisol in March 2014 and launched promotional efforts for the brand in May 2014. As part of the November 12, 2012, Settlement Agreement with Paddock and Perrigo, the Company supplies Perrigo with an Authorized Generic ("Authorized Generic") version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $5.8 million, $9.2 million and $0.3 million during 2014, 2013 and 2012, respectively. In December 2011, the Company discontinued sales of the 400mg Caldolor offering domestically and focused on the 800mg Caldolor offering. During 2014, Cumberland had total sales of $0.5 million of its 400mg Caldolor offering outside the United States. The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.4 million at December 31, 2014 and $0.6 million at December 31, 2013, and the accruals for rebates, product returns and certain administrative and service fees included in other current liabilities were $5.2 million and $2.4 million, respectively, at December 31, 2014 and 2013. Other Revenues During 2013, the Company entered into six new agreements with international partners for commercialization of certain of the Company's products into additional international territories and amended its agreement with Gloria, a Chinese pharmaceutical company, to extend its territory. As a result of the new and amended agreements, the Company recognized approximately $0.6 million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2013. The agreements entered into during 2013 provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the licensing agreements, the Company is entitled to receive additional milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company will recognize revenue for these substantive milestones using the milestone method. The agreements provide for up to $0.6 million in milestone payments related to regulatory approvals and up to $4.0 million in milestone payments related to total and annual product sales. As of December 31, 2014, the Company has not recognized any revenues related to milestones associated with the new agreements. The Company is also entitled to receive royalties on future sales of the products under the agreements. In 2012, the Company entered into an exclusive licensing agreement for Acetadote and Caldolor with Harbin Gloria. In connection with the agreement, the Company has certain protective rights, including the right to review and approve all documents submitted to the Chinese State Drug Administration. During 2012, the Company received nonrefundable, up-front payments totaling approximately $0.7 million in exchange for the transfer of certain intellectual property, including its product dossiers, and recognized these payments as other revenue in the consolidated statement of operations when the intellectual property was provided to the licensee. The licensing agreement provides for the Company to receive additional milestone payments of $0.7 million when the licensee receives notice from the regulatory authority granting approval to conduct clinical trials, or stating that no clinical trials are necessary. The Company is also entitled to receive milestone payments of $1.1 million upon receiving regulatory approval for each of Acetadote and Caldolor in China. The Company will recognize revenue for these substantive milestones using the milestone method. As of December 31, 2014, no revenue has been recognized related to milestones associated with Harbin Gloria. Other revenues during 2014, 2013 and 2012 also includes revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET’s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from SBIR/STTR programs totaled approximately $0.1 million for each of the years ended December 31, 2014, 2013 and 2012.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration